Super Typhoon Nepartak (2016) was used for this case study because it is the most intense typhoon that made landfall in Taiwan in the past decade. Winds extracted from the Climate Forecast System version 2 (CFSV2) and ERA5 datasets and merged with a parametric typhoon model using two hybrid techniques served as the meteorological conditions for driving a coupled wave-circulation model. The computed significant wave heights were compared with the observations recorded at three wave buoys in the eastern waters of Taiwan. Model performance in terms of significant wave height was also investigated by employing the CFSV2 winds under varying spatial and temporal resolutions. The results of the numerical experiments reveal that the simulated storm wave heights tended to decrease significantly due to the lower spatial resolution of the hourly winds from the CFSV2 dataset; however, the variations in the storm wave height simulations were less sensitive to the temporal resolution of the wind field. Introducing the combination of the CFSV2 and the parametric typhoon winds greatly improved the storm wave simulations, and similar phenomena can be found in the exploitation of the ERA5 dataset blended into the parametric wind field. The overall performance of the hybrid winds derived from ERA5 was better than that from the CFSV2, especially in the outer region of Super Typhoon Nepartak (2016).
Core-flow tests with a 3000 mPa.s fuel oil in a 2-inch test facility have revealed important information on the amplitudes and lengths of waves at the oil/water interface. The wavelengths vary considerably with water fraction and oil velocity. Moreover, the flow in the water annulus is turbulent. A previously developed theoretical model for steady core-annular flow in pipes has been extended by incorporating the effect of turbulence in the water film surrounding the oil core. Core-flow pressure gradients predicted by the adapted model coincide very well with measurements provided that actual wave amplitudes and wavelengths observed during these tests are used as input data.
AT-rich interaction domain 1A (ARID1A) is a tumor suppressor gene that mutates in several cancer types, including breast cancer, ovarian cancer, and colorectal cancer (CRC). In colon adenocarcinoma (COAD), the low expression of ARID1A was reported but the molecular reason is unclear. We noticed that ARID1A low expression was associated with increased levels of miR-185 in the COAD. Therefore, this study aims to explore ncRNA-dependent mechanism that regulates ARID1A expression in COAD regarding miR-185. The expression of ARID1A was tested in COAD cell line under the effect of miR-185 mimics compared with inhibitor. The molecular features associated with loss of ARID1A and its association with tumor prognosis were analyzed using multi-platform data from The Cancer Genome Atlas (TCGA), and gene set enrichment analysis (GSEA) to identify potential signaling pathways associated with ARID1A alterations in colon cancer. Kaplan-Meier survival curve showed that a low level of ARID1A was closely related to low survival rate in patients with COAD. Results showed that inhibiting miR-185 expression in the COAD cell line significantly restored the expression of ARID1A. Further, the increased expression of ARID1A significantly improved the prolonged overall survival of COAD. We noticed that there is a possible relationship between ARID1A high expression and tumor microenvironment infiltrating immune cells. Furthermore, the increase of ARID1A in tumor cells enhanced the response of inflammatory chemokines. In conclusion, this study demonstrates that ARID1A is a direct target of miR-185 in COAD that regulates the immune modulations in the microenvironment of COAD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.